HomeProductsBuilding BlocksOrganic Building BlocksAlicyclic HydrocarbonsMometasone
Chemical structure of CAS 105102-22-5

Mometasone

CAS No.105102-22-5
MDL No.N/A
MFC22H28Cl2O4
MW427.40
InChI KeyQLIIKPVHVRXHRI-CXSFZGCWSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Mometasone is an 11beta-hydroxy, 17alpha-hydroxy, 20-oxo, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid, and tertiary alpha-hydroxy ketone. It functions as an anti-inflammatory, dermatologic, vasoconstrictor, and anti-allergic agent, and is related to Delta(1)-progesterone.

CAS No.105102-22-5
Product NameMometasone

Associated Conditions

seasonal allergic rhinitis·otitis media with effusion·sickle cell disease·allergic rhinitis·sinusitis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma.

Clinical therapeutics • Vol. 24, Issue 1 • 2002
PMID: 11833824DOI: 10.1016/s0149-2918(02)85002-0

Instrumental evaluation of retinoid-induced skin irritation.

Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) • Vol. 8, Issue 2 • 2002
PMID: 12060479DOI: 10.1034/j.1600-0846.2002.00330.x

A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • Vol. 88, Issue 6 • 2002
PMID: 12086370DOI: 10.1016/s1081-1206(10)61894-7

Efficacy of budesonide in moderate to severe asthma.

Clinical therapeutics • Vol. 24, Issue 6 • 2002
PMID: 12117080DOI: 10.1016/s0149-2918(02)80005-4

Documentation

Similar Products